SignaLife

Non-invasive Continuous Blood Gas and pH Sensor

Health Tech & Life Sciences
Active
Pre-Seed Tel Aviv-Yafo Founded 2021
Total raised
$2.7M
Last: Pre-Seed 2023-06
Stage
Pre-Seed
Founded
2021
Headcount
5
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences

About

SignaLife is a technology company developing lifesaving AI optic sensors for medical and well-being use. The company’s products are designed to provide non-invasive and continuous pH and Blood Gases for patients hospitalized in the ICU and NICU (neonatal ICU).

Initial results from the company’s first in human trial in Assuta Ashdod ICU, showing high accuracy in testing pH, pCO2, Bi-carbonate (HCO3) and lactate. First baby in the 2nd clinical trial in Sheba Medical Center’s NICU was recruited during April 2025 with promising pH results.

SignaLife’s solutions address the need for non-invasive, reliable measurements, reducing infection risk, minimizing blood draws, and supporting better treatment decisions.

Funding history · 2 rounds · $2.7M total

2023-06
Pre-Seed $1.4M
2022-01
Pre-Seed $800K

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is SignaLife's primary focus?
SignaLife is a technology company developing AI optic sensors for non-invasive and continuous measurement of pH and blood gases in medical settings, specifically for patients in ICU and NICU.
When was SignaLife founded?
SignaLife was founded in March 2021.
What is the total amount of funding SignaLife has raised to date?
SignaLife has raised a total of $2.7 million USD across its funding rounds.
When did SignaLife complete its most recent funding round and how much was raised?
SignaLife completed a Pre-Seed funding round in June 2023, raising $1.4 million USD.
Has SignaLife received any grants?
Yes, SignaLife received a grant of $500,000 USD from the IIA in April 2023.
What are the results of SignaLife's first in-human trial?
Initial results from SignaLife's first in-human trial in Assuta Ashdod ICU showed high accuracy in testing pH, pCO2, Bi-carbonate (HCO3), and lactate.
What is the status of SignaLife's second clinical trial?
The first baby in SignaLife's second clinical trial in Sheba Medical Center’s NICU was recruited during April 2025, showing promising pH results.
How many employees does SignaLife currently have?
SignaLife currently has 5 employees.
Where is SignaLife's headquarters located?
SignaLife's headquarters is located in Tel Aviv-Yafo, Israel.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Monitors
Technologies
Artificial IntelligenceSensing
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 PatentsVerified

Tags

medical-devicesmonitoring